{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kahr MK"],"funding":["German Research Foundation (Deutsche Forschungsgemeinschaft DFG","Texas Medical Center Digestive Disease Center","U.S. Department of Health and Human Services, National Institutes of Health NIH/NICHD","NICHD NIH HHS","NIDDK NIH HHS"],"pagination":["400-406"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9970758"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(4)"],"pubmed_abstract":["<h4>Objective</h4> Obesity in pregnancy bears unique maternal and fetal risks. Obesity has also been associated with chronic inflammation, including elevated serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Higher serum lipopolysaccharide (LPS) levels have been implicated in driving this inflammation, a phenomenon called metabolic endotoxemia (ME). GLP-2, a proglucagon-derived peptide, is believed to be integral in maintaining the integrity of the intestine in the face of LPS-mediated endotoxemia. We hypothesized that obesity and/or excess weight gain in pregnancy would be associated with an increase in maternal and neonatal markers of ME, as well as GLP-2.<h4>Study design</h4> Paired maternal and neonatal (cord blood) serum samples (<i>n</i> = 159) were obtained f"],"journal":["American journal of perinatology"],"pubmed_title":["SERUM GLP-2 is Increased in Association with Excess Gestational Weight Gain."],"pmcid":["PMC9970758"],"funding_grant_id":["SA 2795/2–1","R00HD075858–03","R00HD075858-03","P30DK56338","R00 HD075858","P30 DK056338","SA 2795/2-1"],"pubmed_authors":["Suter MA","Whitham M","Galindo M","Hu M","Kahr MK","Aagaard KM","Antony KM"],"additional_accession":[]},"is_claimable":false,"name":"SERUM GLP-2 is Increased in Association with Excess Gestational Weight Gain.","description":"<h4>Objective</h4> Obesity in pregnancy bears unique maternal and fetal risks. Obesity has also been associated with chronic inflammation, including elevated serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Higher serum lipopolysaccharide (LPS) levels have been implicated in driving this inflammation, a phenomenon called metabolic endotoxemia (ME). GLP-2, a proglucagon-derived peptide, is believed to be integral in maintaining the integrity of the intestine in the face of LPS-mediated endotoxemia. We hypothesized that obesity and/or excess weight gain in pregnancy would be associated with an increase in maternal and neonatal markers of ME, as well as GLP-2.<h4>Study design</h4> Paired maternal and neonatal (cord blood) serum samples (<i>n</i> = 159) were obtained f","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-04T21:47:52.926Z","creation":"2025-04-04T21:47:52.926Z"},"accession":"S-EPMC9970758","cross_references":{"pubmed":["33940644"],"doi":["10.1055/s-0041-1728828"]}}